Abstract
suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 2011;60:1271–7. [8] Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279–99. [9] Tesch GH, Lim AK. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2011;300:F301–10. [10] Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Imaizumi T. Pigment epitheliumderived factor (PEDF) prevents diabetesor advanced glycation end products (AGE)elicited retinal leukostasis. Microvasc Res 2006;72:86–90. [11] Maeda S, Matsui T, Takeuchi M, et al. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol Res 2011;63:241–8. [12] Yamagishi S, Amano S, Inagaki Y, OkamotoT, TakeuchiM,Makita Z. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end productsinduced injury in cultured retinal pericytes. Mol Med 2002;8:546–50. [13] Yamagishi S, Matsui T. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des 2011;17:4379–85.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
